Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:
新澤西州帕西帕尼，2024年11月12日（環球新聞社） - pacira biosciences公司（納斯達克股票代碼：PCRX）今天宣佈將參加以下兩場醫療保健會議上的分析師團隊討論會：
- Jefferies London Healthcare Conference on Tuesday, November 19th at 3:00PM GMT (10:00AM ET).
- 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3rd at 1:00PM ET.
- 傑富瑞倫敦醫療保健會議將於11月19日星期二GMT時間下午3:00（美國東部時間上午10:00）舉行。
- 第36屆派傑投資醫療保健會議將於12月3日星期二下午1:00（美國東部時間）舉行。
Live audio of the events can be accessed by visiting the "Events" page of the company's website at investor.pacira.com. A replay of the webcasts will also be available for two weeks following the events.
會議現場音頻可以通過訪問公司網站investor.pacira.com上的「活動」頁面進行查看。網站還將提供這些活動後兩週內的網絡直播重播。
About Pacira
Pacira BioSciences delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, interscalene brachial plexus nerve block in adults, sciatic nerve block in the popliteal fossa in adults, and adductor canal block in adults for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioverao, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit .
關於Pacira
pacira biosciences提供創新的非阿片類疼痛療法，以改善患者生活。Pacira擁有三種處於商業階段的非阿片類治療產品：EXPAREL（布比卡因脂質體注射懸液），一種長效局部鎮痛藥，目前已獲批用於成人的滲入、筋膜平面阻滯、肩胛間神經叢阻滯、坐骨神經叢阻滯、股四頭肌管阻滯術後疼痛管理；ZILRETTA（曲安特龍緩釋注射液），一種緩釋關節內注射劑，適用於骨關節炎膝關節疼痛治療；iovera，一種新穎的手持設備，通過精確控制的冷溫度劑量作用於靶神經，提供即時、長效的無藥療法疼痛控制。該公司還在推進PCRX-201的開發，這是一種新穎的局部基因治療，具有治療骨關節炎等常見疾病的潛力。要了解有關Pacira的更多信息，請訪問。
CONTACT: Company Contact:
Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
Christian.pedetti@pacira.com
聯繫方式：公司聯繫人：
Pacira BioSciences，Inc。
Christian Pedetti
(973) 254-4387
Christian.pedetti@pacira.com
譯文內容由第三人軟體翻譯。
